CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 132 enrolled
Drug / intervention
ReSTOR +3 +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00963560
NCT00963560Phase 4Completed
CompareCT.gov

A Randomized, Subject-masked Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting IOLs

Alcon Research·interventional·Posted Aug 21, 2009·Updated Aug 9, 2011

In Brief

A Phase 4 clinical trial evaluating ReSTOR +3, Crystalens HD, and 1 other intervention for Cataract. Completed, enrolled 132 participants across 1 site.

Detailed Summary

The purpose of this study is to prospectively evaluate postoperative visual and refractive parameters in a series of subjects bilaterally implanted with Presbyopia-Correcting Intraocular Lenses (IOLs).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 21, 2009
Enrollment StartAug 1, 2009
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 16.9 years ago

Interventions

ReSTOR +3device

Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.

Crystalens HDdevice

Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.

Crystalens AOdevice

Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.